Conference Proceedings

Disease and Patient Characteristics, Patterns of Care, Toxicities, and Outcomes of Chronic Lymphocytic Leukemia (CLL) Patients Treated with Venetoclax: A Multicenter Study of 204 Patients

Anthony R Mato, Constantine S Tam, John N Allan, Danielle M Brander, John M Pagel, Chaitra S Ujjani, Brian T Hill, Nicole Lamanna, Frederick Lansigan, Ryan Jacobs, Mazyar Shadman, Alan P Skarbnik, Jeffrey J Pu, Paul M Barr, Alison R Sehgal, Bruce D Cheson, Clive S Zent, Hande H Tuncer, Stephen J Schuster, Peter V Pickens Show all

BLOOD | AMER SOC HEMATOLOGY | Published : 2017

Grants

Funding Acknowledgements

Mato: Pharmacyclics: Research Funding; AbbVie: Consultancy, Research Funding; DTRM: Research Funding; AstraZeneca: Consultancy; Acerta: Research Funding; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Portola: Research Funding; Regeneron: Research Funding; Janssen: Consultancy; Kite: Consultancy; TG Therapeutics: Membership on an entity's Board of Directors or advisory committees, Research Funding; Gilead Sciences, Inc.: Membership on an entity's Board of Directors or advisory committees. Tam: Janssen Cilag: Honoraria, Research Funding; Roche: Honoraria, Research Funding; Abbvie: Honoraria, Research Funding. Brander: Genentech: Consultancy; Teva Pharmaceuticals, Genentech, AbbVie, Pharmacyclics: Consultancy; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees; TG Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees. Pagel: Gilead: Consultancy; Pharmacyclics: Consultancy. Ujjani: Genentech: Consultancy; Abbvie: Research Funding, Speakers Bureau; Gilead: Consultancy; Pharmacyclics: Consultancy, Research Funding. Lamanna: Gilead: Membership on an entity's Board of Directors or advisory committees, Research Funding. Lansigan: Seattle Genetics: Consultancy; Spectrum Pharmaceuticals: Consultancy, Research Funding. Shadman: Acerta Pharma: Research Funding; Celgene: Research Funding; AbbVie: Other: advisory board; Genentech: Consultancy, Research Funding; TG Therapeutics: Research Funding; Merck: Research Funding; PLEXXIKON: Research Funding; Gilead: Research Funding; Emergent: Research Funding; Pharmacyclics: Other: advisory board, Research Funding. Skarbnik: Seattle Genetics: Speakers Bureau; Genentech: Speakers Bureau; Gilead: Speakers Bureau; Abbvie: Other: Ad board, Speakers Bureau; Novartis: Speakers Bureau. Barr: Seattle Genetics: Consultancy; Infinity: Consultancy; Gilead: Consultancy; Celgene: Consultancy; Novartis: Consultancy; Pharmacyclics LLC, an AbbVie Company: Consultancy, Research Funding; AbbVie: Consultancy, Research Funding. Cheson: Acerta, Pharmacyclics, Epizyme, Gilead, Roche, AbbVi: Other: Institution receives research support; AbbVie, Roche-Genentech, Pharmacyclics, Acerta: Consultancy. Schuster: Celgene: Consultancy, Research Funding; Seattle Genetics: Consultancy; Gilead: Consultancy, Research Funding; Janssen: Consultancy, Honoraria; Bristol-Myers Squibb: Consultancy, Research Funding; Genentech: Consultancy, Research Funding; Merck: Research Funding; Nordic Nanovector: Consultancy; Novartis: Consultancy, Research Funding. Shah: Jazz Pharmaceuticals: Consultancy; Exelixis: Equity Ownership; Oncosec: Equity Ownership; Geron: Equity Ownership. Dorsey: TG Therapeutics, Inc.: Consultancy. Svoboda: BMS: Consultancy, Research Funding; Seattle Genetics: Consultancy, Research Funding; Pharmacyclics: Research Funding; Merck: Research Funding; Celgene: Research Funding; Kite: Consultancy. Furman: Sunesis: Consultancy; Gilead: Consultancy; Abbvie: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Genentech: Consultancy; Pharmacyclics: Consultancy, Honoraria; TG Therapeutics: Consultancy; Verastem: Consultancy.